<- Go home

Added to YB: 2025-02-24

Pitch date: 2024-12-31

NTRA [bullish]

Natera, Inc.

+45.99%

current return

Author Info

No bio for this author

Company Info

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Market Cap

$28.2B

Pitch Price

$158.88

Price Target

N/A

Dividend

N/A

EV/EBITDA

-91.38

P/E

-89.19

EV/Sales

12.92

Sector

Biotechnology

Category

growth

Show full summary:
Alger Small Cap Focus Fund Portfolio Holding: Natera, Inc.

NTRA: Specialty lab for genetic testing in reproductive health, oncology & transplant. Q3 beat on Signatera growth & women's health market share gains. Gross margins expanding on pricing & cost control. Proprietary liquid biopsy platform for cell-free DNA detection. Productivity initiatives like cheaper sequencing to boost earnings.

Read full article (1 min)